Creating a database for patients with immune-mediated inflammatory diseases
Official title: Deployment o the Multidisciplinary Prospective Cohort Imminent
Run by University Hospital, Lille · NCT04334031 · Data updated 2026-11-12
This study is creating a database and biobank for patients with immune-related diseases to see if new information can help improve treatments and understand their conditions better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2200 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | July 20, 2020 |
| Main results expected | July 20, 2031 |
| Study ends | July 21, 2031 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT04334031 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with an IMID who are being treated at Lille University Hospital and can provide informed consent.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to establish a multidisciplinary clinical-biological database and biobank for patients suffering from immune-mediated inflammatory diseases (IMIDs) such as chronic inflammatory disease, angioedema, severe asthma, lupus, and atopic dermatitis. By collecting data and biological samples, the study seeks to identify new prognostic and therapeutic biomarkers that could lead to improved treatment strategies. Patients will be assessed using the SF-12 questionnaire to evaluate their quality of life and disease severity. The research will involve collaboration among various departments at Lille University Hospital.
Why it matters
Potential benefit: If successful, this study could lead to the development of new therapeutic targets and improved management of immune-mediated inflammatory diseases.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for IMIDs, but this approach of creating a comprehensive database is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology) * Social insured * Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures. Exclusion Criteria: * Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system. * Pregnant or breastfeeding woman * Persons deprived of liberty * Protected minors or adults * Persons who have refused or are incapable of giving informed consent * Persons in Emergency Situations
Where it's running
-
Hop Claude Huriez Chu Lille
Lille, France Recruiting
Study contacts
- Principal investigator: David Launay, MD,PhD — University Hospital, Lille
- Study coordinator: David Launay, MD,PhD
- Email: david.launay@chru-lille.fr
- Phone: 03 20 44 42 95
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Baricitinib for people with STAT3‑related Hyper‑IgE (Job) syndrome who have lupus-like disease or atopic dermatitis
This trial will test whether the JAK inhibitor baricitinib can be taken safely and may reduce lupus-like symptoms or severe eczema in people aged 12 and older with STAT3-related Hyper‑IgE (Job) syndrome.
-
Combination treatment for autoimmune disorders using specialized cells and chemotherapy
This study is testing a new combination of specialized cells and chemotherapy to see if it can help people with autoimmune disorders like systemic sclerosis and lupus feel better.
-
A platform for collecting health data on ME/CFS and Long Covid
This study is trying to collect health information from adults with ME/CFS and Long Covid to help researchers better understand these conditions and improve future treatments.
-
Registry and biorepository for rheumatic diseases
This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.
-
Using nivolumab to treat patients with autoimmune disorders and advanced cancer
This study is testing if nivolumab can safely help people with autoimmune disorders who also have advanced cancer by looking at how well it works and what side effects it might cause.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.